Reddit Posts
Mentions
Penny biotechs presenting at the Stephens Virtual Fireside tomorrow and the day after: **$CADL**: adenovirus immuno-onclogy. Float of 45,000,000 shares. 17% insider and 44% institution owned. Biomarker and survival data for CAN-3110 due in Q4 2025; license application for CAN-2409 by Q4 2026. **$INO**: DNA immunotherapy targeting tumours associated with HPV. License application expected *tomorrow*, with full approval by E.O.Y. 2025. **$PYXS**: antibody-drug conjuate (‘first-in-concept’) to ‘defeat difficult-to-treat cancers.’ Float of 42,000,000. 24% insider and 34% institution owned. Various preliminary datas expected Q4 2025. **$SNSE**: human monoclonal IgG1 antibody designed to block the VISTA checkpoint, a T cell suppressor. Float of 1,260,000. 34% owned by insiders and 6% by institutions. Full-dose expansion data for Phase I/II expected by E.O.Y. 2026.
Thoughts on CADL squeeze
UAMY- USAR-NVX- ONDS-ASTS- CADL Which one of these would you recommend for me? I got 9 k to invest so dont know how to mix it up.
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
Add this one I am an advocate of this stock and moreover the potential cancer cure, I really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. Synopsys, we can give those with pancreatic cancer some more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
I'd like to share this story and while i am an advocate of this stock and moreover the potential cancer cure, i really am looking to start a conversation on why companies like CADL are not being picked up by big pharma. They show great clinical results and yet no stock traction or interest. So my post would be as follows if you permit or choose to post yourself.Synopsys, we can give those with pancreatic cancer 5 more years # CAN-2409 (aglatimagene besadenovec) — lead asset * **Modality / claim:** replication-defective adenoviral vector delivering HSV-tk to tumors; given with oral valacyclovir to convert to a local immune-stimulating effect — claimed to enhance tumor antigen release and systemic anti-tumor immunity. Intended across multiple solid tumors (prostate, pancreatic, NSCLC, pancreatic ductal adenocarcinoma (PDAC), etc.). [candeltx.com+1](https://candeltx.com/) * **Clinical evidence / milestones:** reported **positive Phase 3 topline data** in **intermediate-to-high-risk localized prostate cancer** (statistically significant improvement in disease-free survival and strong 2-year biopsy complete response numbers) and positive Phase 2a overall survival signals in PDAC and NSCLC in prior readouts. Those readouts triggered large stock moves when released. [GlobeNewswire+2Wall Street Journal+2](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com) * **Regulatory status:** received **FDA Fast Track designation(s)** (for at least NSCLC and PDAC in prior announcements) and **orphan-drug designation** for pancreatic cancer in the past; company is preparing for a **BLA submission for prostate cancer** targeted (company stated) for **Q4 2026** (management timeline from mid-2025 reporting). SPA agreement on the pivotal prostate trial increases odds that the data would be considered adequate for approval if confirmed. **Not yet approved**. [GlobeNewswire+1](https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html?utm_source=chatgpt.com)
FEMY or SHOT. IDK. Already in MOBX and CADL
MOBX 🚀🚀🚀🚀🚀 CADL -- SUPER undervalued imo
CADL posted this 3 days ago -- idk how it isnt moving Candel Therapeutics Announces CAN-2409 Significantly Improves Disease-Free Survival In Prostate Cancer, Showing Benefit Across Radiation Modalities In Phase 3 Trial
Bought small amounts of BURU, SHOT, CADL
CADL will be making a big announcement on their phase 3 prostate cancer tests this weekend at ASTRO. This is a real catalyst event. Only reason they would wait until ASTRO to present is if it's good news. Small cap stock with good news will 🚀 on Monday.
CADL is expected to have a big announcement of their phase 3 data for prostate cancer treatment at ASTRO this weekend. I'm getting in on that before it takes off.
Not sure if it qualifies but it’s market cap is still under $500 million so I’m going to say CADL. They have an awesome drug pipeline. If it has to truly be under $1, then GBIO. A company with a similar thesis was bought out for $2.1 billion a couple years ago and other big pharma companies almost certainly want to compete in the space. Highly specific delivery of RNA to T cells is going to be huge if they can show it works in humans
CADL is a good one I think. Seems to have been repeatedly brought down by failed drugs, needing to dilute, etc. but now has multiple excellent prospects in the pipeline and share price over $6
Take a look at IOBT, and google it alongside its EIB backing / phase 3 results for a moonshot. CADL looks good too but its more mature (pre-approval). I have positions in both. CRISPR I feel like I missed the boat on?
CADL - late stage trials on a very promising cancer drug with a large total addressable market. I doubt it’s a $100B company. But 10x from here? Absolutely
IOBT & CADL both look good too me.
Right there with you buddy!!! CAPR CADL TGTX SRPT for the win !!!!
Oh that does sound nice. I’ve been in CADL.. part of the same sector. Price target of $26. I think it’ll do well
CADL. Major upgrades, large upside. Excellent phase 3 results.
I was looking at CADL and RGTI this morning when they were both around $7, and I chose to swing trade RGTI.. why god why
CADL did today. Not sure what’s going to happen tomorrow
Today game is CADL, SOXL. IONQ and QBTS..
CADL - tiny market cap, big phase 3 results
HIMS and CADL will take care of you no matter what it is
$CADL to 15$!!!! 🚀💪
Save - price has crashed as they probably will file for bankruptcy. Assets of the company are worth well above the price of stock. Sldp- batteries down because of Trump election apparently because Elon doesn't want subsidies for alternative energy. SLDP has a relationship with DARPA so obviously sldp has been involved in engineering the power system of shit that flies that I can't tell you about because no one knows. Solidpower makes lightweight batteries. Militaries are using drones more and more and powerful lightweight batteries increase the range they can fly in a single mission. CADL has released extraordinary data from treatments for cancer patients in the past and price took off like crazy. It's come back down to earth as they aren't quite far enough along to submit a treatment for FDA approval. They expect to release data from a phase 2 and 3 trial in December.
CADL has effective drugs (essentially vaccines) for lung, brain, prostate and pancreatic cancers in various stages of clinical trials with the next results expected before the end of this year. Market cap is a fraction of many companies with less promising treatments.
Yea it dropped from 11-12 to 4. I think buying some would be a great idea. Candel Therapeutics fell too. Both VSTM and CADL had pancreatic cancer as a research pipeline. Side effects from the treatment affected the stock of VSTM.
CADL dipped 50% bcs shorties, but there are big NEWS!
Some big move afterhours in the biotech sector: https://www.globenewswire.com/news-release/2024/05/23/2887676/0/en/Candel-Therapeutics-Reports-Prolonged-Overall-Survival-in-Phase-2-Clinical-Trial-of-CAN-2409-for-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-in-Patients-Non-Responsive-to-Immune-Chec.html $CADL +33% https://www.businesswire.com/news/home/20240523300933/en/Verastem-Oncology-Announces-Positive-Initial-Interim-Safety-and-Efficacy-Results-from-RAMP-205-Trial-Evaluating-Avutometinib-Plus-Defactinib-in-Combination-with-Gemcitabine-and-Nab-paclitaxel-in-First-Line-Metastatic-Pancreatic-Cancer%E2%80%8B $VSTM +55%
Perhaps.. and I know this concept is crazy.. learning to trade. Then you won't have to rely on "meme stocks". SMCI NVDA where great plays and have been for a while. CADL has had a nice run. EH made many opportunities the past year. Opportunities everyday. Why trade meme stocks? They are trash. They been trash. Use your brain.
I have over 50% in CADL. I believe it is one of the most undervalued biotech stocks on the market. Their market cap is a small fraction of other biotechs with the same or less success. Their clinical trials are producing amazing results that seem likely to change the way cancer is treated.
CADL is a buy right now imo, they’re releasing some interesting and promising stuff it seems
Anyone on here talking about Candel Therapeutics Inc. CADL$
CADL was mentioned a few times on April 4/5 in the daily lounge thread. Crazy rise on that first day.
Why has no one in this group talked about CADL? I swear outside of KULR nobody here ever mentions great plays
On Friday CADL went up over 400%. Was up over 500% for a bit. Guess who had some? Me :{}
I am thinking that because there too much biopharma stock that is trending this week that is why the volume in x4 was so low, most of the attention are in XXII and CADL, the next few weeks are gonna pop for XFOR
Stop sleeping on CADL, why r none of you regards talking about this & more news coming by end of Q2 and Q4 2024.
Bought a fuck ton of CADL, good luck bois
CADL is very interesting right now. Seems to be fluctuating quite a bit on a Pancreas cancer vaccine.
This CADL volume is crazy
who cashed out on $CADL? literally climbed 400% from opening yesterday. crazt
Anyone know if CADL is legit ?
I was on CADL yesterday in at $3.17, got out at $6.40, reached almost $10 at post. Might be an interesting one to watch on the pre
Ya just going to ignore CADL??
Don't make moves until Moring of, but Keeping an eye on CADL, jumped 340% today after an announcement about cancer drug
Candel Theurapeutics (CADL) seems to be going up a lot. There is news they are making progress in cancer treatment.
See below pump and dump stocks below in today market wat is SEC doing ✅1️⃣ TVGN Long > 5.17 Short < 4.60 ✅2️⃣ RELI Long > 0.6210 Short < 0.5399 ✅3️⃣ HWH Long >2.49 Short < 2.25 ✅4️⃣ ZCMD Long > 2.10 Short < 1.91 ✅5️⃣ CADL Long > 2.09 Short < 1.87
Those are junk stocks ' - see message below Some random site published this at 8.50 am ✅1️⃣ TVGN Long > 5.17 Short < 4.60 ✅2️⃣ RELI Long > 0.6210 Short < 0.5399 ✅3️⃣ HWH Long >2.49 Short < 2.25 ✅4️⃣ ZCMD Long > 2.10 Short < 1.91 ✅5️⃣ CADL Long > 2.09 Short <1.97
CADL 500% gain today, fuck I cut my profits at 70% holy shiet
is no one aware of how crazy $CADL did today??? literally insane
LFG! I'm positive lifetime P/L after today too. CADL stocks long.
I settled for a 10% gain on CADL at $3.3 The price is now at $6.7 and I’m kicking myself for not holding. Sometimes you just can’t catch a break! 
$CADL just kept going up...halted now
$CADL is popping off right now 👀 I got in late but still making a decent little profit off of it
$CADL rising Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-interim-data-randomized/
CADL Candel Therapeutics…it about to explode in next couple of weeks
CADL running. Cancer cure potential
CADL about to go off , Stage 3 approval potentially